We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · January 04, 2022

PD-L1 Inhibition in STK11– and KEAP1–Mutant Lung Adenocarcinoma Affected by KRAS Mutation Status

Journal of Thoracic Oncology


Additional Info

Journal of Thoracic Oncology
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
J Thorac Oncol 2021 Nov 02;[EPub Ahead of Print], B Ricciuti, KC Arbour, JJ Lin, A Vajdi, N Vokes, L Hong, J Zhang, MY Tolstorukov, YY Li, LF Spurr, AD Cherniack, G Recondo, G Lamberti, X Wang, D Venkatraman, JV Alessi, VR Vaz, H Rizvi, J Egger, AJ Plodkowski, S Khosrowjerdi, S Digumarthy, H Park, N Vaz, M Nishino, LM Sholl, D Barbie, M Altan, JV Heymach, F Skoulidis, JF Gainor, MD Hellmann, MM Awad

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading